இந்தியன் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இந்தியன் கண்டுபிடிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இந்தியன் கண்டுபிடிப்பு Today - Breaking & Trending Today

SucSEED Indovation backs EdTech virtual community platform EventBeep

SucSEED Indovation backs EdTech virtual community platform EventBeep
techstory.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techstory.in Daily Mail and Mail on Sunday newspapers.

Ramesh Loganathan , Venkatesh Prasad , Mycaptain Ed , Eunimart Vdezi , Dhiraj Kumar Sinha , Saurabh Mangrulkar , Vikrant Varshney , Rakhi Pal Venkatesh Prasad , Rakhi Pal , Core Members Gps Of The Fund , Indovation Fund , Lax Chepuri Co , Building Community At College Level , Cummins College Of Engineering Womens , Indian College , Investment Of Sucseed Angel Network , Sucseed Angel Network , Venture Capital Angel Fund , Seed Fund , Current Portfolio Of Sucseed Indovation Fund , Building Inclusive Student Community , Realtytech City Solutions , Sucseed Indovation Fund , Other Gps Of The Fund , Business Development , Founder Partner Of Sucseed Indovation Fund ,

Zydus Cadila DCGI nod hepatitis drug COVID19 treatment use

URL copied
Zydus Cadila seeks DCGI nod for use of hepatitis drug for COVID-19 treatment
Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for the additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which the company sells under the brand name PegiHep has shown promising results in treating COVID-19, Zydus Cadila said in a statement.
The interim results indicate that the drug when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease, it added. ....

United States , Zydus Cadila , Sharvil Patel , Zydus Group , Drug Administration , Image Source , Drugs Controller General , Pegylated Interferon , Pegylated Interferon Alpha , Indian Innovation , United States Food , Cadila Healthcare , Dgci Nod , Hepatitis Drug , Covid 19 Treatment , Covid 19 , Corona Virus , Coronavirus Treatment , Drugs Controller General Of India , Alpha 2b , ஒன்றுபட்டது மாநிலங்களில் , ஜய்துச் காடிலா , ஷார்வில் படேல் , ஜய்துச் குழு , படம் மூல , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,

Zydus' COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod

Zydus COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod
Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the standard of care arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients
BusinessToday.In | April 5, 2021 | Updated 12:51 IST
Interim results show PegIFN could help patients recover faster, avoiding complications seen in the advanced stages
Zydus Cadila announced on Monday, April 5 that it has sought approval from drug regulator DCGI (Drugs Controller General of India) for its drug Pegylated Interferon Alpha 2b (PegIFN) to be used in the treatment of COVID-19 patients. The domestic pharma company has applied for an approval for additional indication with DCGI for the use of PegIFN, announcing that its phase-III clinical trials with the drug have manifested promising results in treating coronavirus patients. ....

Zydus Cadila , Sharvil Patel , Cadila Healthcare Ltd , Drugs Controller General , Pegylated Interferon Alpha , Interferon Alpha , Pegylated Interferon , Indian Innovation , Managing Director , Zydus Cadila Covid 19 Drug , Drugs Controller General Of India , Pegylated Interferon Alpha 2b , Pegifn Drug , Moderate Covid 19 Patients , Zydus Cadila Phase 3 Trials , Coronavirus In India , Covid 19 In India , ஜய்துச் காடிலா , ஷார்வில் படேல் , காடிலா சுகாதாரம் லிமிடெட் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , இந்தியன் கண்டுபிடிப்பு , நிர்வகித்தல் இயக்குனர் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ஆஃப் இந்தியா , ஜய்துச் காடிலா கட்டம் சோதனைகள் ,

Zydus Cadila seeks DCGI nod for use of hepatitis drug for Covid-19 treatment | India News

Representative image (AFP)
NEW DELHI: Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator drugs controller general of India (DCGI) for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating Covid-19.
Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name PegiHep has shown promising results in treating Covid-19, Zydus Cadila said in a statement.
The interim results indicate that the drug when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease, it added. ....

United States , Zydus Cadila , Sharvil Patel , Zydus Group , Pegylated Interferon , Pegylated Interferon Alpha , Indian Innovation , Cadila Healthcare , India News , India News Today , Today News , Google News , Breaking News , ஒன்றுபட்டது மாநிலங்களில் , ஜய்துச் காடிலா , ஷார்வில் படேல் , ஜய்துச் குழு , இந்தியன் கண்டுபிடிப்பு , காடிலா சுகாதாரம் , இந்தியா செய்தி , இந்தியா செய்தி இன்று , இன்று செய்தி , கூகிள் செய்தி , உடைத்தல் செய்தி ,

Zydus seeks DCGI approval for using PegIFN in COVID-19 treatment

91.15% of patients treated with PegIFN were RT PCR negative by day 7 as compared to
78.90% on the standard of care (SOC) arm ....

Pegihep Peg , Zydus Cadila , Sharvil Patel , Cadila Healthcare Ltd , Pegylated Interferon Alpha , Signal Transduction , Targeted Therapy , Managing Director , Pegylated Interferon , Indian Innovation , Covid 19 , ஜய்துச் காடிலா , ஷார்வில் படேல் , காடிலா சுகாதாரம் லிமிடெட் , சமிக்ஞை கடத்தல் , இலக்கு சிகிச்சை , நிர்வகித்தல் இயக்குனர் , இந்தியன் கண்டுபிடிப்பு ,